Company Profiles

driven by the PitchBook Platform

Aileron Therapeutics

Description

Developer of biologics for the treatment of cancer. The company applies its proprietary cell permeable peptide technology to generate therapeutics for the treatment of cancer. It develops a proprietary peptide technology platform stapled peptides convert a range of therapeutically useful peptides into pharmaceitically tractable molecules.

2001

Founded

PRIVATE

Status

11-50

Employees

Series E1

Latest Deal Type

$33M

Latest Deal Amount

$111M

Total Amount Raised

Description

Developer of biologics for the treatment of cancer. The company applies its proprietary cell permeable peptide technology to generate therapeutics for the treatment of cancer. It develops a proprietary peptide technology platform stapled peptides convert a range of therapeutically useful peptides into pharmaceitically tractable molecules.

Website:

www.aileronrx.com

Formerly Known As

Renegade Therapeutics

Ownership Status

Privately held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Drug Discovery

Primary Office

281 Albany Street Cambridge, MA 02139United States +1 (617) 995-0900
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore Aileron Therapeutics's full profile, request a free trial.

Aileron Therapeutics Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

Aileron Therapeutics Cap Table

Stock# of Shares
Authorized
Par ValueDividend Rate (%)Original
Issue Price
LiquidationLiquidation
Pref. Multiple
Conversion
Price
% Owned

Aileron Therapeutics Investors (6)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
AJU IB InvestmentVenture CapitalMinority000 0000000 0000
Apple Tree PartnersVenture CapitalMinority000 0000000 0000
Excel Venture ManagementVenture CapitalMinority000 0000000 0000
Lilly VenturesCorporate Venture CapitalMinority000 0000000 0000
Novartis Venture FundsCorporate Venture CapitalMinority000 0000000 0000
AJU IB Investment Venture Capital
Apple Tree Partners Venture Capital
Excel Venture Management Venture Capital
Lilly Ventures Corporate Venture Capital
Novartis Venture Funds Corporate Venture Capital

Aileron Therapeutics Executive Team (10)

NameTitleBoard
Seat
Contact
Info
Joseph Yanchik IIICo-Founder, Chief Executive Officer & Director
Evan LippmanBusiness Officer, Chief Financial Officer & Senior Vice President
Jiawen HanDirector
Krzysztof DarlakDirector, Peptide Production
Karen OlsonHead, In Vivo Pharmacology
Joseph Yanchik III Co-Founder, Chief Executive Officer & Director
Evan Lippman Business Officer, Chief Financial Officer & Senior Vice President
Jiawen Han Director
Krzysztof Darlak Director, Peptide Production
Karen Olson Head, In Vivo Pharmacology

Aileron Therapeutics Board Members (7)

NameRepresentingRoleSinceContact
Info
Armen Shanafelt Ph.DLilly VenturesGeneral Partner000 0000
Caleb WinderExcel Venture ManagementCo-Founder & Managing Director000 0000
Elliot Ehrich MDSelfScientific Advisory Board Member000 0000
John McArthurSelfBoard Member000 0000
Reinhard Ambros Ph.DNovartis Venture FundsPresident000 0000
Armen Shanafelt Ph.D General Partner Lilly Ventures
Caleb Winder Co-Founder & Managing Director Excel Venture Management
Elliot Ehrich MD Scientific Advisory Board Member Self
John McArthur Board Member Self
Reinhard Ambros Ph.D President Novartis Venture Funds
Request full access to PitchBook